Why McKesson (MCK) is a Top Momentum Stock for the Long-Term

McKesson shares rose 5.6% over the past four weeks, and four analysts raised fiscal 2027 earnings estimates in the last 60 days, lifting the consensus by $0.18 to $44.73 per share. The company reported nearly $41 billion in GLP-1 revenue in FY25 and an average earnings surprise of +4.3%; Zacks rates MCK #3 (Hold), with a Momentum Score of B and VGM Score of A.

Analysis

The signal here is weaker than the headline framing: a small upward revision to FY27 EPS alongside a Zacks #3/“Hold” is not a clear earnings inflection. The key underwriting issue is whether GLP-1 scale translates into incremental gross profit and cash generation, not headline sales. Pharmaceutical distribution is a high-volume, low-margin model; rapid product growth can lift reported revenue without proportionate earnings, and may increase working-capital needs. Verify segment-level contribution, cash conversion, and guidance before treating GLP-1 exposure as a durable multiple driver.

Over the next 1–3 months, the catalyst is company-reported evidence that specialty and oncology growth is supporting profit growth—not simply volume—or broader upward estimate revisions. Over 6–18 months, continued GLP-1 demand could benefit McKesson and competitors such as Cencora and Cardinal Health, but the market may be over-crediting distributors for economics captured elsewhere in the drug channel. Payer, manufacturer, or channel changes that compress distributor economics would challenge the thesis. The article supplies no valuation, segment margin, or cash-flow evidence, so it does not support a price target or a high-conviction momentum chase.

Key Decisions for Investors

• No fresh position on this promotional momentum signal alone. Treat the modest estimate revisions as a watch item; confirm the next results show earnings and cash-flow follow-through before adding MCK exposure.
• If already long, retain only while guidance and cash conversion validate growth. Reassess on any guidance reduction, weakening segment profit contribution, or persistent divergence between reported sales growth and operating cash flow.
• For a relative-value screen, compare MCK with Cencora and Cardinal Health on earnings revisions, valuation, cash conversion, and specialty/GLP-1 profit contribution; do not assume the largest reported product revenue implies the best economics.
• Falsification watch: estimates reverse, management commentary indicates weaker GLP-1 economics or working-capital absorption, or reported growth fails to translate into operating profit. Missing data to verify: segment-level margins, GLP-1 gross-profit contribution, and cash conversion.